Skip to main content
Erschienen in: Supportive Care in Cancer 11/2006

01.11.2006 | Supportive Care International

Financial and family burden associated with cancer treatment in Ontario, Canada

verfasst von: Christopher J. Longo, Margaret Fitch, Raisa B. Deber, A. Paul Williams

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

To determine the financial and family resources burden associated with the treatment of cancer. A questionnaire was developed to determine the direct monthly “out-of-pocket costs” (OOPC), the indirect costs, and the associated perceived family burden.

Materials and methods

A self-administered questionnaire using a quota sample from five cancer clinics in Ontario, Canada was given to 282 cancer patients (74 breast, 70 colorectal, 68 lung, and 70 prostate). Monthly OOPC were obtained for: drugs, home care, homemaking, complementary and alternative medicines, vitamins and supplements, family care, travel, parking, accommodations, devices, and others. The questionnaire asked if OOPC for treatment were a burden, and if others took time from work to provide caregiving.

Main results

The mean monthly OOPC was $213, with an additional $372 related to imputed travel costs. For those patients who responded that the burden was “significant” (16.5%), their OOPC was $452. In the case of patients responding that their burden was “unmanageable” (3.9%), their OOPC was $544. The survey showed that 35.6% of patients required others to take time from work and this was higher in the under-65 category. The mean number of days lost from work in the previous 30 days for these caregivers was 7 days.

Conclusions

These results suggest the financial burden is problematic for 20% of this sample. The caregivers’ lost time from work influence this burden, and for 36% of this sample, it amounts to one third of their working days in any given month. Policies and programs to address these gaps are needed.
Literatur
1.
Zurück zum Zitat Alter DA, Naylor CD, Austin P et al (1999) Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 341(18):1359–1367CrossRefPubMed Alter DA, Naylor CD, Austin P et al (1999) Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 341(18):1359–1367CrossRefPubMed
2.
Zurück zum Zitat Alter DA, Iron K, Austin PC et al (2004) Socioeconomic status, service patterns, and perceptions of care among survivors of acute myocardial infarction in Canada. JAMA 291(9):1100–1107CrossRefPubMed Alter DA, Iron K, Austin PC et al (2004) Socioeconomic status, service patterns, and perceptions of care among survivors of acute myocardial infarction in Canada. JAMA 291(9):1100–1107CrossRefPubMed
3.
Zurück zum Zitat Barer ML, Evans RG, Stoddart GL (1979) Controlling health care costs by direct charges to patients: snare or delusion? Ontario Economic Council occasional paper no. 10. Ontario Economic Council, Toronto Barer ML, Evans RG, Stoddart GL (1979) Controlling health care costs by direct charges to patients: snare or delusion? Ontario Economic Council occasional paper no. 10. Ontario Economic Council, Toronto
4.
Zurück zum Zitat Birenbaum LK (1992) Terminal care costs in childhood cancer. Pediatr Nursing 18:285–288 Birenbaum LK (1992) Terminal care costs in childhood cancer. Pediatr Nursing 18:285–288
5.
Zurück zum Zitat Browne GB, Arpin K, Corey P, Fitch M, Gafni A (1990) Individual correlates of health service utilization and the cost of poor adjustment to chronic illness. Med Care 28(1):43–58CrossRefPubMed Browne GB, Arpin K, Corey P, Fitch M, Gafni A (1990) Individual correlates of health service utilization and the cost of poor adjustment to chronic illness. Med Care 28(1):43–58CrossRefPubMed
6.
Zurück zum Zitat Carlson LE, Bultz BD (2003) Cancer distress screening: needs, models and methods. J Psychosom Res 55:403–409CrossRefPubMed Carlson LE, Bultz BD (2003) Cancer distress screening: needs, models and methods. J Psychosom Res 55:403–409CrossRefPubMed
7.
Zurück zum Zitat Doran E, Robertson J, Rolfe I et al (2004) Patient co-payments and use of prescription medicines. Aust N Z J Public Health 28(1):62–67PubMed Doran E, Robertson J, Rolfe I et al (2004) Patient co-payments and use of prescription medicines. Aust N Z J Public Health 28(1):62–67PubMed
8.
Zurück zum Zitat Dunlop S, Coyte PC, McIssac W (2000) Socio-economic status and the utilization of physicians’ services: results from the Canadian National Population Health Survey. Soc Sci Med 51:123–133CrossRefPubMed Dunlop S, Coyte PC, McIssac W (2000) Socio-economic status and the utilization of physicians’ services: results from the Canadian National Population Health Survey. Soc Sci Med 51:123–133CrossRefPubMed
9.
Zurück zum Zitat Evans C, Crawford B (1999) Patient self-reports in pharmacoeconomic studies: their use and impact on study validity. Pharmacoeconomics 15(3):241–256CrossRefPubMed Evans C, Crawford B (1999) Patient self-reports in pharmacoeconomic studies: their use and impact on study validity. Pharmacoeconomics 15(3):241–256CrossRefPubMed
11.
Zurück zum Zitat Guidry JJ, Aday LA, Zhang D, Winn RJ (1998) Cost considerations as potential barriers to cancer treatment. Cancer Pract 6(3):182–187CrossRefPubMed Guidry JJ, Aday LA, Zhang D, Winn RJ (1998) Cost considerations as potential barriers to cancer treatment. Cancer Pract 6(3):182–187CrossRefPubMed
12.
Zurück zum Zitat Houts PS, Lipton A, Harvey HA, Martin B, Simmonds MA, Dixon RH, Longo S, Andrews T, Gordon RA, Meloy J, Hoffman SL (1984) Non-medical costs to patients and their families associated with outpatient chemotherapy. Cancer 53(11):2388–2392CrossRefPubMed Houts PS, Lipton A, Harvey HA, Martin B, Simmonds MA, Dixon RH, Longo S, Andrews T, Gordon RA, Meloy J, Hoffman SL (1984) Non-medical costs to patients and their families associated with outpatient chemotherapy. Cancer 53(11):2388–2392CrossRefPubMed
13.
Zurück zum Zitat Huang J, Zhou S, Groome P et al (2001) Factors affecting the use of palliative radiotherapy in Ontario. J Clin Oncol 19(1):137–144PubMed Huang J, Zhou S, Groome P et al (2001) Factors affecting the use of palliative radiotherapy in Ontario. J Clin Oncol 19(1):137–144PubMed
14.
Zurück zum Zitat Johnson RE, Goodman RM, Hornbrok MC et al (1997) The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care 35:1119–1131CrossRefPubMed Johnson RE, Goodman RM, Hornbrok MC et al (1997) The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care 35:1119–1131CrossRefPubMed
15.
Zurück zum Zitat Moore K (1998) Out-of-pocket expenditures of outpatients receiving chemotherapy. Oncol Nurs Forum 25(9):1615–1622PubMed Moore K (1998) Out-of-pocket expenditures of outpatients receiving chemotherapy. Oncol Nurs Forum 25(9):1615–1622PubMed
16.
Zurück zum Zitat Organization for Economic Co-operation and Development (OECD) (2004) Organization for Economic Co-operation and Development (OECD) health data. A comparative analysis of 30 OECD countries (CD-ROM). OECD, Paris, France Organization for Economic Co-operation and Development (OECD) (2004) Organization for Economic Co-operation and Development (OECD) health data. A comparative analysis of 30 OECD countries (CD-ROM). OECD, Paris, France
17.
Zurück zum Zitat Paszat LF, MacKillop WJ, Groome PA et al (1998) Radiotherapy for breast cancer in Ontario: rate variation associated with region, age and income. Clin Invest Med 21(3):125–134PubMed Paszat LF, MacKillop WJ, Groome PA et al (1998) Radiotherapy for breast cancer in Ontario: rate variation associated with region, age and income. Clin Invest Med 21(3):125–134PubMed
18.
Zurück zum Zitat Public Health Agency of Canada (1998) Economic burden of illness in Canada. November 2002 Public Health Agency of Canada (1998) Economic burden of illness in Canada. November 2002
19.
Zurück zum Zitat Riley GF, Potosky AL, Lubitz JD et al (1995) Medicare payments from diagnosis to death for aged cancer patients by state at diagnosis. Med Care 33:828–841CrossRefPubMed Riley GF, Potosky AL, Lubitz JD et al (1995) Medicare payments from diagnosis to death for aged cancer patients by state at diagnosis. Med Care 33:828–841CrossRefPubMed
20.
Zurück zum Zitat Roberts RO, Bergstralh EJ, Schmidt L, Jacobsen SJ (1996) Comparison of self-reported and medical record health care utilization measures. J Clin Epidemiol 49(9):989–995CrossRefPubMed Roberts RO, Bergstralh EJ, Schmidt L, Jacobsen SJ (1996) Comparison of self-reported and medical record health care utilization measures. J Clin Epidemiol 49(9):989–995CrossRefPubMed
21.
Zurück zum Zitat Ryan M, Birch S (1991) Charging for heath care: evidence on the utilization of NHS prescribed drugs. Soc Sci Med 33:681–687CrossRefPubMed Ryan M, Birch S (1991) Charging for heath care: evidence on the utilization of NHS prescribed drugs. Soc Sci Med 33:681–687CrossRefPubMed
22.
Zurück zum Zitat Soumerai SB, McLaughlin TJ, Ross-Degnan D et al (1994) Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 331:650–655CrossRefPubMed Soumerai SB, McLaughlin TJ, Ross-Degnan D et al (1994) Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 331:650–655CrossRefPubMed
23.
Zurück zum Zitat Spitzer WO, Roberts RS, Delmore T (1976) Nurse practitioners in primary care. V. Development of the utilization and financial index to measure effects of their deployment. CMAJ 114(12):1099–1102 Spitzer WO, Roberts RS, Delmore T (1976) Nurse practitioners in primary care. V. Development of the utilization and financial index to measure effects of their deployment. CMAJ 114(12):1099–1102
24.
Zurück zum Zitat Stommel M, Given CW, Given BA (1993) The cost of cancer home care to families. Cancer 71(5):1867–1874CrossRefPubMed Stommel M, Given CW, Given BA (1993) The cost of cancer home care to families. Cancer 71(5):1867–1874CrossRefPubMed
25.
Zurück zum Zitat Tamblyn R, Laprise R, Hanley JA et al (2001) Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285(4):421–429CrossRefPubMed Tamblyn R, Laprise R, Hanley JA et al (2001) Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285(4):421–429CrossRefPubMed
26.
Zurück zum Zitat Weissman JS, Levin K, Chasan-Taber S, Massagli MP, Seage GR, Scampini L (1996) The validity of self-reported health-care utilization by AIDS patients. AIDS 10(7):775–783PubMedCrossRef Weissman JS, Levin K, Chasan-Taber S, Massagli MP, Seage GR, Scampini L (1996) The validity of self-reported health-care utilization by AIDS patients. AIDS 10(7):775–783PubMedCrossRef
Metadaten
Titel
Financial and family burden associated with cancer treatment in Ontario, Canada
verfasst von
Christopher J. Longo
Margaret Fitch
Raisa B. Deber
A. Paul Williams
Publikationsdatum
01.11.2006
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2006
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0088-8

Weitere Artikel der Ausgabe 11/2006

Supportive Care in Cancer 11/2006 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.